Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension

References

• Bryant‐Greenwood GD, Schwabe C. Human relaxins: Chemistry and biology. Endocr Rev 1994; 15: 5–26
   PubMed Web of Science ®Google Scholar
• Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205–234
   PubMed Web of Science ®Google Scholar
• Bani D. Relaxin: a pleiotropic hormone. Gen Pharmacol 1997; 28: 13–22
   PubMedGoogle Scholar
• Geddes BJ, Summerlee AJS. The emerging concept of relaxin as a centrally acting peptide hormone with hemodynamic actions. J Neuroendocrinol 1995; 7: 411–417
   PubMed Web of Science ®Google Scholar
• Conrad KP, Novak J. Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2004; 287: R250–R261
   Web of Science ®Google Scholar
• Mohaupt M. Molecular aspects of preeclampsia. Mol Aspects Med 2007; 28: 169–191
   PubMed Web of Science ®Google Scholar
• Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264–272
   PubMed Web of Science ®Google Scholar
• Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender‐specific phenotype. Cardiovasc Res 2003; 57: 395–404
   PubMed Web of Science ®Google Scholar
• Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46: 412–418
   PubMed Web of Science ®Google Scholar
• Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005; 46: 745–750
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108
   PubMed Web of Science ®Google Scholar
• Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic‐ angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7–11
   PubMed Web of Science ®Google Scholar
• Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27: 1753–1760
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527–1533
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605
   PubMed Web of Science ®Google Scholar
• Pauca AL, O′Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38: 932–937
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525: 263–270
   PubMed Web of Science ®Google Scholar
• Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–1089
   PubMed Web of Science ®Google Scholar
• Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieère P, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–1415
   PubMed Web of Science ®Google Scholar
• Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 2005; 28: 191–202
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann NY Acad Sci 2005; 1041: 441–443
   PubMed Web of Science ®Google Scholar
• Xu Q, Lekgabe ED, Gao XM, Ming Z, Tregear GW, Dart AM, et al. Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 2008; 149: 476–482
   PubMed Web of Science ®Google Scholar
• Parry LJ, Poterski RS, Summerlee AJS. Effects of relaxin on blood pressure and the release of vasopressin and oxytocin in anesthetized rats during pregnancy and lactation. Biol Reprod 1994; 50: 622–628
   PubMed Web of Science ®Google Scholar
• Ward DG, Cronin MJ, Baertschi AJ. Lack of cardiovascular and vasopressin responses to human relaxin in conscious, late pregnant rats. Am J Physiol 1991; 261: 206–211
   Google Scholar
• Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 2007; 49: 1202–1206
   PubMed Web of Science ®Google Scholar
• Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?. Circulation 2002; 106: 292–295
   PubMed Web of Science ®Google Scholar
• Failli P, Nistri S, Mazzetti L, Chiappini L, Bani D. Effects of relaxin on vascular smooth muscle and endothelial cells in normotensive and hypertensive rats. Ann N Y Acad Sci 2005; 1041: 311–313
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001; 15: 2187–2195
   PubMed Web of Science ®Google Scholar
• Kupari M, Mikkola TS, Turto H, Lommi J. Is the pregnancy hormone relaxin an important player in human heart failure?. Eur J Heart Fail 2005; 7: 195–198
   PubMed Web of Science ®Google Scholar
• Krüger S, Graf J, Merx MW, Stickel T, Kunz D, Hanrath P, et al. Relaxin kinetics during dynamic exercise in patients with chronic heart failure. Eur J Intern Med 2004; 15: 54–56
   PubMedGoogle Scholar
• Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N‐terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003; 89: 879–881
   PubMed Web of Science ®Google Scholar